Sun Pharmaceuticals rating – Buy- One-offs hit bottomline in Q4FY22
时间:2024-06-26 08:28:50 阅读(143)
Sun reported net loss of Rs 22.8 bn in Q4, mainly on one-offs of Rs 39.4 bn (Rs 37.2 bn of provisions related to settlement of antitrust litigation for valganciclovir, valsartan and esomeprazole, Rs 1.6 bn of provisions for settlement with various purchaser groups and Rs 563.5 m for restructuring of certain businesses). It also booked a one-off tax gain of Rs 764.2 m and FX gain of Rs 1.6 bn. Adjusting for one-offs and FX, PAT was Rs 14.2 bn (~19% below HSBCe). EBITDA margins at 23.1% fell 109bps y-o-y and 346bps q-o-q on input cost pressure and normalisation of expenses.
Traction continues for specialty sales: Global sales for the specialty products portfolio of $185 m grew ~33% y-o-y (+1% q-o-q) on strong traction in key brands Ilumya, Cequa, and Odomzo. Specialty sales in FY22 grew 42% to $673 m (13% of total revenues vs 7% in FY18). Global sales for Ilumya (incl. milestones and royalties) reached $315 m (+81% y-o-y). Winlevi (novel acne drug launched in Nov 2021) is seeing good traction and around 9K prescribing doctors (out of 15K) have prescribed it. We expect sales traction to continue for key brands on improving patient footfall (elective procedures are not yet back to pre-COVID-19 levels), better commercial execution and increasing market size.
Retain Buy rating: We remain positive on Sun’s efforts in the specialty products portfolio, which we believe will likely achieve Ebitda breakeven over the next 2-3 years, resulting in significant operating leverage. We assume specialty sales to be key driver of US sales, with sales CAGR of 17.2% for FY22-25e, while we assume base generic and Taro sales stabilising at current levels.
Sun plans to expand India sales headcount by 10% in FY23e to improve market coverage and de-clutter some marketing divisions. We assume its India segment sustaining above-market growth on new launches and better reach. The outlook remains largely steady for other segments (RoW, emerging markets, API, etc.) barring any short-term fluctuations. Post Q4, we adjust our estimates per current visibility leading to 3.3%/3.5% cuts in EPS for FY23/24e. Our TP is Rs 1,040 (from Rs 1,075).
上一篇:Dipam seeks advisor, consultant to manage Bharat Bond ETF’s Rs 50,000 crore asset
下一篇:Will Nifty hold onto gains or fall below 17400- 8 things to know before stock market opens
猜你喜欢
- Dana keen on ‘make in India’ to boost India market share, expects $700 million revenue from electrification
- Dense fog causes 14 trains delay in Delhi-NCR; fog layer continues to remain, says IMD
- Diwali Muhurat Trading 2022- BSE, NSE to open for 1 hour today; check market, trade modifications timings
- Gold Price Today, 9 May- Gold to be range-bound; investors eye US CPI for rate hike clues
- Will Nifty top 18,800 or fall in trade- See SGX Nifty, FII data, US Fed verdict, more before market opens
- Despite high cane dues, sugarcane sowing up 4% in UP
- Govt sets 2022-23 grain production target at 328 mt, up 4% on year
- Dalmia Bharat share nosedives in intra-day trade but brokerage show optimism; check target levels and recommendations
- DreamFolks IPO share allotment- Check status via BSE, Link Intime, grey market premium; stock listing on Sep 6